Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC.

Published byIndra Sonny Johan Modified over 5 years ago

Similar presentations

Presentation on theme: "Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC."— Presentation transcript:

1 Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD.
Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. (A) Untreated 24-week-old NPC cats showed significantly fewer Purkinje cells per unit length compared to age-matched normal control cats (*P < 0.05). Cats (24 weeks old) receiving 30 mg of IC HPβCD or greater showed significantly greater Purkinje cell numbers compared to untreated NPC cats (†P < 0.05). In contrast, 24-week-old cats treated postsymptomatically with 120 mg of IC HPβCD at 16 weeks of age showed significantly fewer Purkinje cells compared to normal control cats (*P < 0.05). (B) Untreated 24-week-old NPC cats showed no significant difference in hearing threshold compared to normal control cats. In contrast, cats receiving 7.5 or 120 mg of HPβCD developed significant increases in hearing threshold compared to untreated NPC cats (†P < 0.05). Individual cats receiving lower doses of HPβCD also showed elevated hearing thresholds, although, as a group, these were not significant. (C) At 76 weeks of age, all NPC cats receiving 30 mg of HPβCD or greater showed significant elevations in hearing threshold. *P < Charles H. Vite et al., Sci Transl Med 2015;7:276ra26 Copyright © 2015, American Association for the Advancement of Science

Download ppt "Fig. 8. Purkinje cell quantification and hearing threshold in NPC cats administered IC HPβCD. Purkinje cell quantification and hearing threshold in NPC."

Similar presentations

CD facilitates RCT in vivo and promotes urinary cholesterol excretion

CD facilitates RCT in vivo and promotes urinary cholesterol excretion
NRP1-expressing myeloid cells contribute to adipose tissue vascularization. NRP1-expressing myeloid cells contribute to adipose tissue vascularization.

NRP1-expressing myeloid cells contribute to adipose tissue vascularization. NRP1-expressing myeloid cells contribute to adipose tissue vascularization.
Fig. 2. CD treatment facilitates regression of murine atherosclerosis.

Fig. 2. CD treatment facilitates regression of murine atherosclerosis.
Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.

Fig. 6 Transmissibility of adiposity from humanized mice to germ-free recipients. Transmissibility of adiposity from humanized mice to germ-free recipients.
Fig. 7 Correlation of NHP and human ISGs.

Fig. 7 Correlation of NHP and human ISGs.
Differentiation of AZD4785 from MAPK pathway inhibitors in vitro

Differentiation of AZD4785 from MAPK pathway inhibitors in vitro
Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.

Fig. 4. Peanut-specific TH2A cells are specifically targeted during immunotherapy. Peanut-specific TH2A cells are specifically targeted during immunotherapy.
Fig. 4 Altitudinal distributions of ice thickness change (m year−1) for the 650 glaciers. Altitudinal distributions of ice thickness change (m year−1)

Fig. 4 Altitudinal distributions of ice thickness change (m year−1) for the 650 glaciers. Altitudinal distributions of ice thickness change (m year−1)
Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.

Fig. 5 Quantitative assessment of the efficacy of the tissue-engineered implant to heal the TMJ disc defect. Quantitative assessment of the efficacy of.
Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.

Fig. 3. The effect of VRC01 infusion on virus load in plasma and blood CD4 T cells during ART. The effect of VRC01 infusion on virus load in plasma and.
Consolidated Standards of Reporting Trials flow diagram of VRC trial

Consolidated Standards of Reporting Trials flow diagram of VRC trial
Fig. 4 Labeling of Msmeg with DMN-Tre is fast and specific and depends on Ag85A function. Labeling of Msmeg with DMN-Tre is fast and specific and depends.

Fig. 4 Labeling of Msmeg with DMN-Tre is fast and specific and depends on Ag85A function. Labeling of Msmeg with DMN-Tre is fast and specific and depends.
Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.

Fig. 2. Clinically actionable somatic genomic alterations in various tumor types. Clinically actionable somatic genomic alterations in various tumor types.
Filipin staining of marginal gyrus of cerebral cortex in NPC cats

Filipin staining of marginal gyrus of cerebral cortex in NPC cats
Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.

Fig. 5. Microarray analysis of tumors treated by dabrafenib, trametinib, or the combination of dabrafenib and trametinib with pmel-1 ACT or mock ACT. Microarray.
Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.
Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.

Fig. 7 Bacterial dependency networks in IgA deficiency and HDs.
Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.

Fig. 6. TIV-09, but not MIV-09, induces an IFN signature in the blood of vaccinated individuals at day 1. TIV-09, but not MIV-09, induces an IFN signature.
Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.

Fig. 3 M7824 inhibits tumor growth and metastasis and provides long-term antitumor immunity. M7824 inhibits tumor growth and metastasis and provides long-term.
Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Fig. 4. The effect of combined inhibition of BCL-2 and BCR-ABL on leukemia LT-HSC frequency. The effect of combined inhibition of BCL-2 and BCR-ABL on.

Similar presentations

Ads by Google